Skip to main content

Sickle Cell Disease and cannabis in Alabama

The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Listed qualifying condition
✓ Yes
LEGAL
Physician-certified med…
POSSESSION
$65/yr
STATE FEE
7–30 d
TIMELINE
Listed qualifying condition. The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Alabama statute and program

The Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) is the operating authority for Alabama patient certification. The authoritative legal text is: Alabama Compassion Act (SB 46 of 2021).

What the evidence says about cannabis and Sickle Cell Disease

Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by mutations in the hemoglobin gene. Red cells assume a rigid sickle shape under low-oxygen conditions, leading to chronic hemolytic anemia, episodic vaso-occlusive pain crises, stroke risk, acute chest syndrome, and progressive end-organ damage. SCD disproportionately affects people of African, Mediterranean, and South Asian descent.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Sickle Cell Disease page.

How to qualify in Alabama

The Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) requires the following registration steps for a Sickle Cell Disease patient (or any qualifying diagnosis):

  1. See an Alabama-licensed certifying physician. Under the Darren Wesley "Ato" Hall Compassion Act (Alabama Act 2021-450), only physicians who have completed the four-hour Alabama Medical Cannabis Commission (AMCC) certification course and registered with the AMCC may certify patients. The physician evaluates the patient for one of the enumerated qualifying conditions (autism, cancer-related cachexia or chronic pain, Crohn’s, depression, epilepsy, HIV/AIDS, panic disorder, Parkinson’s, PTSD, sickle-cell, intractable pain, terminal illness, and others under §20-2A-3).
  2. Register through the AMCC patient portal. After certification, the patient creates an account in the AMCC patient registry using a current Alabama driver license or state ID. The physician’s certification is linked electronically to the patient’s record. Caregivers (required for minor patients) register separately and pass a state and federal background check.
  3. Pay the $65 state registration fee. The annual AMCC patient registration fee is $65 (caregiver registration is also $65). Once paid, the patient receives a digital medical cannabis card. The program does not yet have brick-and-mortar dispensaries open as of the program’s phased launch — operating dispensary licenses were issued in 2024 with retail expected to begin in 2025.
  4. Purchase from an AMCC-licensed dispensary. With the digital card and Alabama ID, patients may purchase Alabama-permitted forms (tablets, capsules, tinctures, gels, oils, gummies, lozenges, suppositories, topical patches, transdermal patches, nebulizers, and liquids or oils for use in an inhaler — no smokable flower, edibles intended to look like candy, or vaping products under §20-2A-3(15)). Adult-use cannabis remains illegal in Alabama.
State registration fee
$65
Physician visit (typical)
$200–$400
Certification to card
7–30 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Alabama registration steps, fees, and reciprocity rules, see the Alabama cannabis-laws page.

ICD-10 code

A certifying physician documenting Sickle Cell Disease for the Alabama medical cannabis program will typically record ICD-10 D57.1 or SNOMED-CT 417357006 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Alabama list Sickle Cell Disease as a qualifying condition for medical cannabis?

Yes. Alabama explicitly lists Sickle Cell Disease as a qualifying condition under Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act). A patient with a documented Sickle Cell Disease diagnosis can pursue state-program certification with a physician registered in the state. The qualifying-condition list is set by state statute or regulation and may change. Inclusion on the list does not guarantee certification — a physician still has to evaluate the patient and decide that medical cannabis is appropriate for that specific case under Alabama rules.

How do I get a Alabama medical marijuana card for Sickle Cell Disease?

Step one is finding a physician licensed in Alabama who is registered with Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) and willing to evaluate Sickle Cell Disease cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Alabama does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Sickle Cell Disease?

For Sickle Cell Disease, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Sickle Cell Disease lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Sickle Cell Disease should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Sickle Cell Disease and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Sickle Cell Disease; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Alabama Compassion Act (SB 46 of 2021)accessed May 16, 2026
  2. Alabama Medical Cannabis Commissionaccessed May 16, 2026
  3. Wikipedia: Cannabis in Alabamaaccessed May 16, 2026
  4. Ala. Code §13A-12-214: Unlawful possession of marijuana (penalty schedule)accessed May 17, 2026
  5. Alabama SB 46 (2021): Darren Wesley 'Ato' Hall Compassion Actaccessed May 17, 2026
  6. Alabama Department of Agriculture & Industries: Industrial Hemp Programaccessed May 17, 2026
  7. Alabama Legislature bill trackeraccessed May 17, 2026
  8. NIH National Heart, Lung, and Blood Institute: Sickle Cell Diseaseaccessed May 15, 2026
  9. NIH NCCIH: Cannabis (Marijuana) and Cannabinoidsaccessed May 15, 2026